Dihydroartemisinin- Piperaquine Versus Artemether- Lumefantrine in the Treatment Uncomplicated Plasmodium Falciparum Malaria in Sudan
NCT ID: NCT01075945
Last Updated: 2010-02-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE4
140 participants
INTERVENTIONAL
2010-02-28
2010-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Dihydroartemisinin- piperaquine
orally tablets
Dihydroartemisinin- piperaquine
three tablets per day
artemether- lumefantrine
twenty tablet in eight doses
artemether- lumefantrine
oral tablets
artemether- lumefantrine
twenty tablet in eight doses
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Dihydroartemisinin- piperaquine
three tablets per day
artemether- lumefantrine
twenty tablet in eight doses
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Pregnancy
5 Years
95 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Southeast University, China
OTHER
University of Khartoum
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Univeristy of Khartoum
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Sinnar
Cinnar, Blue Nile, Sudan
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Ishag Adam, Md, PhD
Role: primary
Fatih M Malik, MD
Role: backup
References
Explore related publications, articles, or registry entries linked to this study.
Adam I, Elmardi KA, Malik EM. Predictors of antimalarial treatment failure in an area of unstable malaria transmission in eastern Sudan. Trans R Soc Trop Med Hyg. 2009 Jan;103(1):21-4. doi: 10.1016/j.trstmh.2008.07.005. Epub 2008 Aug 20.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DP v AL01aasudan
Identifier Type: OTHER
Identifier Source: secondary_id
wadadam
Identifier Type: -
Identifier Source: secondary_id
DP v AL01
Identifier Type: -
Identifier Source: org_study_id